Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Assets (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Assets readings, the most recent being $20.0 million for Q1 2026.

  • On a quarterly basis, Assets fell 67.77% to $20.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.0 million, a 67.77% decrease, with the full-year FY2025 number at $20.2 million, down 81.45% from a year prior.
  • Assets hit $20.0 million in Q1 2026 for Atara Biotherapeutics, down from $20.2 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $436.1 million in Q2 2022 to a low of $20.0 million in Q1 2026.
  • Median Assets over the past 5 years was $165.3 million (2024), compared with a mean of $187.3 million.
  • Biggest five-year swings in Assets: dropped 19.59% in 2022 and later crashed 81.45% in 2025.
  • Atara Biotherapeutics' Assets stood at $376.4 million in 2022, then tumbled by 56.03% to $165.5 million in 2023, then crashed by 34.08% to $109.1 million in 2024, then crashed by 81.45% to $20.2 million in 2025, then fell by 1.18% to $20.0 million in 2026.
  • The last three reported values for Assets were $20.0 million (Q1 2026), $20.2 million (Q4 2025), and $30.2 million (Q3 2025) per Business Quant data.